Cathie Wood Portfolio: 5 Biggest Losers

2. Adaptive Biotechnologies Corporation (NASDAQ:ADPT)

Number of Hedge Fund Holders: 25  

Year-to-Date Decline in Share Price: 52%

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) develops and markets treatments for various diseases. The stock has slumped since March when Genentech, owned by pharma giant Roche, suspended collaboration with Adaptive Biotech for the development of a cancer drug.  

ARK Investment Management owned 4.8 million shares in Adaptive Biotechnologies Corporation (NASDAQ:ADPT) at the end of September 2021 worth $165 million, representing 0.39% of the portfolio. 

At the end of the third quarter of 2021, 25 hedge funds in the database of Insider Monkey held stakes worth $1.7 billion in Adaptive Biotechnologies Corporation (NASDAQ:ADPT), down from 27 in the preceding quarter worth $2.2 billion.